Can CRISPR/Cas9 off-target genomic editing be avoided? Ways to improve target specificity

Have you tried to generate knock-out or knock-in cell lines using CRISPR/Cas9 in your lab only to find that genes other than your intended target were affected as well? In this webinar, we will review current data on improving the fidelity of CRISPR/Cas9, including better ways to design the sgRNA, and using the double nickase mutant form of Cas9 to avoid off-target effects. We will also discuss best practices in quality control against potential off-target effects and how our GenCRISPR™ service can provide you with a high-quality, genome edited cell line.

Speaker-related Webinars

Introduction to immune checkpoints – the new hot target for cancer immunotherapy

Development of therapeutic antibodies against immune checkpoints for the treatment of melanoma and other cancers is gaining momentum among academia and the pharmaceutical industry.

Learn More

Leveraging GenScript’s cytokines, antibodies, and protein purification tools to explore Ideas for your next grant

Wouldn't it be great if all the supplies you needed to obtain preliminary data for your next grant were available from the same vendor? This webinar will show you how to incorporate

Learn More

Recombinant protein applications: choosing the best cytokine, growth factor or chemokine for your experimental system

Are you treating cells in vitro? Do your in vivo studies investigate changes in the immune response or tumor growth?

Learn More

Stem cell culture: choosing the best conditions for optimal expansion and differentiation

Are you finding your rate of stem cell differentiation to be less than optimal? Choosing the appropriate conditions for stem cell expansion and differentiation is critical for obtaining a high yield of properly differentiated cells

Learn More

Biologics Drug Discovery: Steps to Achieving an Antibody Drug Candidate

In the past decade, drug discovery has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology.

Learn More